Revvity (RVTY) Q3 2025 10-Q Quarterly Report
Revvity (RVTY) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 28, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Revvity Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $698.9M for Q3 FY25, up 2% YoY from $684.0M; Life Sciences up 1% to $342.8M, Diagnostics up 3% to $356.1M
- • Gross margin 53.6% for Q3 FY25, down 2.66 pts YoY from 56.3%, cost of revenue 46.4% vs 43.7% YoY due to tariffs and FX impact
- • Life Sciences segment operating income $101.0M, down 9% YoY; Diagnostics segment operating income $89.4M, down 5% YoY
- • Operating cash flow $407.0M for nine months FY25, down $82.5M YoY; increased stock repurchases $652.5M vs $184.4M prior year
- • Management expects ~20% effective tax rate FY25; ongoing tariff impact prompting mitigation strategies; new $1B share repurchase authorized through 2027
Risk Factors
- • New risk: Increased customer spending caution due to recent U.S. funding and regulatory uncertainties undermining purchase timing and volumes
- • Updated risk: More costly or less effective risk mitigation due to recent market developments affecting hedging and insurance strategies
- • Regulatory risk: Failure to comply with FDA and international laws may cause recalls, fines, criminal penalties, or halt of product distribution
- • Operational risk: Supply chain disruptions from limited single source suppliers, geopolitical conflicts, or tariffs risking delays and increased costs
- • Financial risk: Exposure to fluctuations in foreign currency exchange rates impacting results; effects compounded by inflation and interest rate changes
Revvity Q3 2025 Quarterly FinancialsXBRL
Revenue
$699M
▲ +2.2% YoY▼ -3.0% QoQ
Net Income
$47M
▼ -50.6% YoY▼ -13.5% QoQ
Net Margin
6.7%
▼ -712bp YoY▼ -82bp QoQ
Source: XBRL data from Revvity Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Revvity Quarterly Reports
Get deeper insights on Revvity
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.